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Different neurodegenerative disorders, such as Alzheimer’s disease (AD) and 
 frontotemporal dementia (FTD), lead to dementia syndromes. Dementia will pose a huge 
impact on society and thus it is essential to develop novel tools that are able to detect the 
earliest, most sensitive, discriminative, and dynamic biomarkers for each of the disorders. 
To date, the most common assays used in large-scale protein biomarker analysis are 
enzyme-linked immunosorbent assays (ELISA), such as the sandwich immunoassays, 
which are sensitive, practical, and easily implemented. However, due to the novelty of 
many candidate biomarkers identified during proteomics screening, such assays or the 
antibodies that specifically recognize the desired marker are often not available. The 
development and optimization of a new ELISA should be carried out with considerable 
caution since a poor planning can be costly, ineffective, time consuming, and it may lead 
to a misinterpretation of the findings. Previous guidelines described either the overall bio-
marker development in more general terms (i.e., the process from biomarker discovery to 
validation) or the specific steps of performing an ELISA procedure. However, a workflow 
describing and guiding the main issues in the development of a novel ELISA is missing. 
Here, we describe a specific and detailed workflow to develop and validate new ELISA 
for a successful and reliable validation of novel dementia biomarkers. The proposed 
workflow highlights the main issues in the development of an ELISA and covers several 
critical aspects, including production, screening, and selection of specific antibodies 
until optimal fine-tuning of the assay. Although these recommendations are designed 
to analyze novel biomarkers for dementia in cerebrospinal fluid, they are generally appli-
cable for the development of immunoassays for biomarkers in other human body fluids 
or tissues. This workflow is designed to maximize the quality of the developed ELISA 
using a time- and cost-efficient strategy. This will facilitate the validation of the dementia 
biomarker candidates ultimately allowing accurate diagnostic conclusions.
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introduction
Advancing age is the greatest risk factor of dementias, such as 
Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and 
frontotemporal dementia (FTD). As life span increases, dementia 
will impose a huge social and economic burden with more than 
100 million of individuals predicted to suffer from dementia by 
2050 worldwide (1). Up to now, there are no adequate treatment 
options to halt progression of the various types of neurodegen-
erative diseases leading to dementia. To be able to tailor treat-
ment, it is important to determine the underlying pathological 
processes and the stage of progression of these processes at the 
individual level, before irreversible damage is done. Thus, there 
is a great interest in developing specific, sensitive, and practical 
tools to differentially diagnose and discriminate the different 
types of dementia in their earliest possible phase (i.e., AD, FTD, 
DLB, vascular dementia, etc.). Although the currently available 
cerebrospinal fluid (CSF) biomarkers for AD [i.e., amyloid β (Aβ), 
total Tau (t-Tau), and phosphorylated Tau (p-Tau) (2, 3)] have 
a high sensitivity and specificity for AD, there is still no test to 
effectively predict the development of AD in a pre-symptomatic 
stage (4). In addition, there are no biomarkers available for the 
diagnosis of other types of dementia, such as FTD or DLB (5). 
This can be partially attributed to the limited knowledge about 
the etiological factors underlying the neuropathology of the dif-
ferent disorders. Thus, there is an urgent need to unravel novel 
pathways and proteins in order to find new biomarkers reflecting 
the pathogenesis of the different dementia syndromes (i.e., AD, 
DLB, FTD), which will likely promote the development of novel 
alternative diagnostic and therapeutic strategies.
Global protein profiling by mass spectrometry (MS)-based 
proteomics has evolved as a new hypothesis-free (unbiased) 
avenue to optimally unravel new candidate protein biomarkers 
involved in different diseases, including neurodegenerative 
disorders (6). The sensitivity, speed, and the practicability of the 
different proteomics approaches has improved rapidly over the 
years (7, 8), leading to the discovery of an enormous number of 
biomarker candidates (9, 10). Most of the identified biomarker 
candidates have not yet been validated, which hampers their 
implementation in clinical practice (8). In order to facilitate the 
validation process, a coherent pipeline has been suggested for 
the development of novel biomarkers, which divides the overall 
process into four phases: discovery, qualification, verification, 
and validation (Figure 1) (11). Due to the high number of can-
didates identified in the discovery phase by unbiased proteomics 
[ranging between twenty and several hundred (10)], and the costs 
of assay development and validation, a prioritize selection of the 
discovered biomarker candidates should be performed (12) based 
on (i) the fold-change between control and disease cases, (ii) 
the possible relationship of the candidate with the pathological 
mechanisms, (iii) supporting literature, and/or (iv) the availabil-
ity of the reagents to detect a specific target.
Noteworthy, unbiased-MS can only analyze a limited number 
of samples which, together with the extensive sample preparation 
required, leads to high false positive rate (13). Thus, the subsequent 
qualification phase serves to identify the potential false positive 
candidates and to confirm the differential abundance of the 
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FiGURe 1 | Pipeline reflecting the development on novel protein 
biomarker candidates. Biomarker development pipeline is divided into four 
main phases. Biomarker development starts with a low throughput screening 
of samples in the unbiased phase to a high throughput analysis in the latest 
clinical validation stage, where hundreds to thousands of samples are 
evaluated for the clinical assessment of the biomarker candidate. “Analytes” 
and “Samples” refer to the number of different protein targets or samples, 
respectively, that are evaluated in each phase. LC-MS/MS, liquid 
chromatography tandem mass spectrometry; MRM, multiple reaction 
monitoring; IHC, immunohistochemistry; WB, Western blotting. Figure 
adapted from Rifai et al. (11).
selected proteins using an alternative targeted methodology (11). 
During verification, prioritized markers are specifically analyzed 
in a larger cohort of samples. Among all the different technologies 
that are able to detect a specific protein in the qualification and 
verification phases, targeted proteomics [i.e., multiple reaction 
monitoring (MRM)] is a compelling option due to the higher 
accuracy and sensitivity compared to unbiased MS-approaches 
(10, 14). However, those techniques may not be readily available. 
Alternatively, antibody-based techniques [i.e., Western blotting, 
immunohistochemistry, enzyme-linked immunosorbent assays 
(ELISA)] can be used for qualification and verification. Due to 
the unbiased nature of the discovery phase, however, the specific 
reagents needed may not be commercially available, which will be 
the next critical issue during the validation phase. During valida-
tion, the reliability of the corresponding molecule as a biomarker 
is tested with the use of a highly specific assay that allows high 
throughput screening of samples.
To date, the most accepted assay for biomarker validation is 
ELISA since it can measure numerous samples simultaneously 
with low variation (11). In addition, its use does not require highly 
qualified expertise or technology, allowing its implementation in 
every laboratory (14). Though different immunoassay formats 
are available, sandwich ELISA is the most common assay used in 
biomarker analysis due to its high specificity and sensitivity (15). 
In this format, the target protein will be detected using two dif-
ferent antibodies (capture and detection antibodies). For many of 
the candidate biomarkers, a commercially available assay will not 
exist and specific antibodies against the target of interest and/or 
the corresponding ELISA need to be developed. The development 
and optimization of an ELISA requires a careful design since a 
wide range of variables, ranging from the antibody specificity to 
the concentration and composition of the different reagents, can 
affect the final result and therefore the validity of the biomarker 
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FiGURe 2 | Recommended workflow for the development of a novel eLiSA. Workflow to facilitate the development and analytical validation of assays for the 
validation of novel biomarker candidates. The process is divided into four different steps (orange rectangles). In each step, different analyses are performed (dark 
gray rectangles) and specific questions are addressed before moving into the next phase (light gray circles). When the different criteria in a specific phase cannot be 
reached, changes should be performed one phase back. If a specific ELISA is already available, it should undergo a validation process for the targeted matrix 
(step 3). JPND-BIOMARKAPD guidelines are published in this special issue by Andreasson and colleagues.
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candidate. Thus, a careful design can reduce the development 
costs and ineffectiveness, and will probably lead to more accurate 
analytical outcomes. Previous guidelines described either the 
overall biomarker development in more general terms (i.e., the 
process from biomarker discovery to validation) (11) or how to 
perform the ELISA procedure itself (15), but not the main issues 
regarding the development of optimal ELISA for novel protein 
biomarker candidates in CSF. Here, we suggest a step-by-step 
workflow (Figure 2) to facilitate the development of new ELISA’s 
and the validation of novel biomarker candidates based on the 
literature available and our own best practice. In each step, differ-
ent key issues need to be tested (Table 1). An estimated time-line 
for every step is also provided.
Antibody Design, Production, and Selection
Antibody Design
The specificity and sensitivity of the antibody are the critical 
determinants defining the quality of an ELISA (16). It is essential 
that the antibodies used in the ELISA recognize the native protein 
or protein fragments in order to avoid sample processing and 
minimize variation of the final outcome. Noteworthy, the samples 
used to discover biomarker candidates are denatured, reduced, 
and trypsinized prior to analysis for the proteomics workup. 
Thus, the results of the unbiased approach provide information 
about unique peptides derived from proteins that are differently 
regulated between clinical groups. It is therefore important to 
have information about the protein characteristics, such as its 3D 
structure, hydrophobicity, post-translational modifications, and/
or binding sites. For instance, an antibody developed against an 
epitope detected in the proteomics study that belongs to a highly 
hydrophobic or glycosylated part of the protein may not be suit-
able for ELISA since the corresponding epitope is masked under 
native conditions (17) (Figure  3A). Protein characteristics are 
accessible in different databases, such as the Universal Protein 
Resource (UniProt) or the protein data bank (PDB) (18, 19), but 
are also provided by companies specialized in antibody produc-
tion. In addition, a novel online platform named Protter is very 
useful to get an overall representation of the target protein in which 
different annotations, including previous proteomics results or 
TABLe 1 | Critical issues of biomarker immunoassays.
workflow step Key issue
1. Antibody production Antibody design: optimal epitope selection
Antibody production: polyclonal antibodies using 
peptides
Internal control sample preparation
Antibody selection: specificity tests
2. ELISA development Optimal antibody pair selection (titration 
checkerboard)
Assay set-up: concentrations, blocking buffers, etc.
Biomarker candidate qualification
3. ELISA validation JPND-BIOMARKAPD guidelines
Pre-analytical confounding factors
4. Biomarker clinical 
assessment
Large cohort analysis: power analysis
Biomarker sensitivity/specificity: AUC, ROC
Reproducible results: multi-center studies
CSF, cerebrospinal fluid; LOD, limit of detection, LOQ, limit of quantitation, AUC, 
area under the curve, ROC, receiver operating characteristic. JPND-BIOMARKAPD 
guidelines published in this special issue by Andreasson and colleagues.
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the known protein characteristics (binding and transmembrane 
domains, post-translational modifications, or cleavage sites) are 
presented (Figure 3B) (20).
immunogen Selection
Based on the need to detect the native protein or protein frag-
ments during the analysis to avoid sample processing, the optimal 
immunogen for antibody production should be the purified or 
recombinant full-length protein (21). However, the production 
and purification of full-length proteins is usually time consum-
ing, costly and challenging from a technical perspective [i.e., 
aberrant protein folding, cells stress, solubility issues, etc. (22)]. 
In addition, the epitope recognized by the developed antibody 
might ultimately not be specific for the targeted native protein 
but rather to a general conformational state (17). Thus, it may be 
more effective to start antibody production using highly specific 
peptides. During peptide selection one should always consider: 
(i) the location of the peptide within the native protein and the 
post-translational modifications of the different epitopes within 
the protein to increase the chance that antibodies will detect the 
native protein and (ii) consider the peptide-ranges identified in 
the unbiased approach, since those are known to be differentially 
expressed in the clinical groups.
Polyclonal vs. Monoclonal Antibodies
It is important to decide whether to use and produce polyclonal 
or monoclonal antibodies, which have their own advantages and 
disadvantages (23). Monoclonal antibodies are usually used in 
ELISA since, unlike polyclonals, they benefit from being derived 
from an indefinite source to produce exactly the same antibody 
(i.e., hybridoma cells), which significantly reduces batch-to-batch 
variation. Moreover, monoclonal antibodies are considered to be 
more specific than polyclonal since they recognize a single epitope. 
Nevertheless, if a small peptide is used for animal immunization 
(i.e., 15 amino acid), the different epitopes that the polyclonal 
antibodies can recognize are limited, equating the specificity 
between monoclonal and polyclonal antibodies. In addition, the 
time and thus the costs needed to produce monoclonal antibodies 
are considerably higher than those for polyclonal antibodies, 
which are therefore often chosen in early development stages. 
Rabbits are commonly used for polyclonal antibody production 
if there is no identified need for a specific animal species (i.e., 
remarkably large amounts of antibody needed) due to its easy 
handling, size, high titer, and high-affinity antiserum (24). Thus, 
we suggest starting with the production of polyclonal antibodies 
recognizing at least five different epitopes (one epitope per animal) 
within the protein. The affinity purification of the produced anti-
bodies will remarkably increase the chances of obtaining specific 
signals. Large-scale production of monoclonal antibodies can 
start once the most reactive antibody to the targeted biomarker 
in the desired matrix is defined and the optimal antibody pairs 
for ELISA are identified.
Whenever available, it is recommended to select commercial 
antibodies based on a demonstrated high specificity (by, e.g., 
Western Blot of CSF or brain tissue) and described suitability for 
ELISA. In this respect, several initiatives that provide information 
about the antibodies available and their validation procedure are 
currently ongoing, such as the Antibody initiative of the Human 
Proteome Organization (25) or the Swedish Human Proteome 
Resource Program (26). Production of polyclonal antibodies may 
last at least 2 months (Figure 3C).
Antibody Reactivity and Specificity
The specificity and reactivity of the different affinity-purified 
antibodies in different matrices (i.e., immunogen, CSF, tissue) can 
be tested using simple techniques, such as dot blot and Western 
blot. Some antibodies might be already excluded when no reac-
tivity is observed (Figure 4A). In order to optimally compare the 
data between the different experiments, it is recommended to 
define and select a specific set of samples to be used continuously 
as internal controls (positive control sample) (27). For instance, 
individual CSF samples can be pooled into the different clinical 
groups (i.e., controls and AD) and aliquoted in order to have 
a large number of the same sample available. Pre-analytical 
variables (i.e., freeze/thaw cycles, storage temperature) affect 
the measurements of the CSF biomarkers (28–30) and thus the 
final outcome of the analyses. It is therefore important to follow 
specific guidelines for storage and handling of the CSF samples 
used in order to minimize the effect of possible pre-analytical 
bias already in this stage of development (31, 32). Since CSF is 
likely reflecting the biochemical alterations ongoing in the brain 
(33), it is conceivable to find changes of the identified proteins 
in brain tissue as well. Thus, when available, it is recommended 
to include also post-mortem brain tissue homogenates as it usu-
ally shows highly reactive bands. Noteworthy, our experience is 
that the height of the specific bands identified in brain tissue 
homogenates on Western blot is not identical to those in the CSF.
Testing antibody specificity in human samples can be chal-
lenging due to the lack of “pure” positive and negative controls 
(i.e., human samples lacking/overexpressing the target protein). 
Different types of reagents can be used to define specificity such as 
the recombinant full-protein, cell lysates, and/or animal tissue in 
which the target protein is overexpressed and/or downregulated 
(21). However, final conclusions for the specificity in human CSF 
or post-mortem tissue based only on reactivity observed in cells 
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FiGURe 3 | Antibody design and production. (A) Schematic representation of a protein amino acid sequence in denatured/reducing conditions (upper) or in its 
native form (bottom). Green amino acids represent the peptides recognized by unbiased proteomics in the discovery phase. Antibodies (Y symbol), glycol groups 
(black dots), and disulfide bonds (dotted line) are also represented. Specific epitopes detected in the unbiased proteomics approach might be available in denatured 
conditions but might be masked in native conditions. (B) Graphical representation of a transmembrane protein using Protter (20), in which all protein characteristics 
are included. (C) Time-line differences in the production of polyclonal and monoclonal antibodies.
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lysates or animal tissue must be drawn with due caution since this 
reactivity may not accurately represent the physiological form of 
the protein present in humans (21).
Antibody pre-adsorption with the antigenic peptide is also 
an easy and cost-effective alternative to test antibody specific-
ity. If the signal obtained by Western blot using the antibody 
against the target matrix (e.g., CSF) is specific, it should be 
abrogated or remarkably reduced when the antibody is blocked 
with the antigenic peptide and be unaffected if similar but not 
identical peptides are used (34, 35). Unmodified reactivity after 
antibody pre-adsorption is non-specific and may derive from 
secondary antibody interactions or by contamination with other 
antibodies in the antibody solution (i.e., when the antibody has 
not been optimally affinity-purified). The reduced reactivity 
after antibody pre-adsorption does however not provide direct 
evidence of the specificity of the antibody, since the binding of 
the antibody to non-target proteins will be also inhibited. Thus, 
while persistent reactivity after pre-adsorption will indicate 
that the antibody is bad, reduced reactivity does not guarantee 
that the antibody is good (21, 36). Nonetheless, the binding to 
non-target proteins is unlikely to happen when antibodies have 
been produced against a unique sequence for the target protein. 
Further indirect evidence of antibody specificity comes from 
the comparison between the different antibodies, which should 
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FiGURe 4 | Recommended experiments during antibody testing for an optimal selection of antibodies. (A) Example of a dot blot against CSF, human 
brain, or antigenic peptide using two antibodies recognizing two different epitopes of the same protein at different concentrations. (B) Two different samples 
analyzed by Western blot under reducing (+DTT) and non-reducing (−DTT) conditions and detected by two antibodies (Ab1 and Ab2) detecting two different 
epitopes of the same protein. Only Ab 2 can detect the protein of interest in CSF in native conditions. (C) Schematic representation exemplifying a checkerboard 
titration to test different antibody pairs for ELISA development. In this set-up, one antibody (Ab1) is used as capture antibody in three different concentrations (2 and 
1 μg/mL and no capture antibody (−)). Four different antibodies are tested as detection antibodies (Ab 2–5) in four different dilutions (1:100, 1:1000, 1:5000, and no 
detection antibody (−)). A fixed concentration of the standard protein/peptide is used in every well (i.e., 0.5 μg/mL). The best combination will be the one giving the 
highest signal using the lowest amount of antibody (higher dilution) and with the lowest background (signal when no antibody is used).
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give a similar reactivity pattern (35). In addition, homologs of 
the target protein may exist. If the recombinant homologous 
protein/fragments or the antibodies against the homologous 
protein are available, it is recommended not only to compare the 
reactivities between the antibodies but also to test whether the 
newly developed antibodies targeting the biomarker candidate 
can recognize homologous proteins. Those analyses will help to 
rule out possible cross-reactivity.
Direct evidence of the specificity could be obtained via 
isolation of the proteins recognized by the antibody through 
immunopurification (IP) followed by mass-spectrometry 
analysis. Those analyses can however be costly and time 
consuming since larger amounts of human CSF samples are 
usually needed to obtain a meaningful signal and to prepare 
the negative controls (IP without antibody and/or with an 
irrelevant antibody), and protein isolation from the antibody–
protein complex may result difficult due to a strong binding.
Based on the resources available, a combination of the 
different approaches should be applied to determine the 
specificity of the different antibodies, as it was previously 
done for the monoclonal antibody that was subsequently 
used for a specific ELISA against Aβ40 and not to other Aβ 
forms (37).
Recognition of Specific Physiological Protein 
Forms
For a successful ELISA development, it is important to know 
the different possible conformational states of the target protein 
(monomers, dimers, aggregates) in the corresponding matrix 
(i.e., CSF) and thus samples should be analyzed under different 
denaturing and reducing conditions (Figure 4B). In addition to 
Western blotting, it is recommended to analyze samples via direct 
ELISA, in order to further test which antibodies are able to rec-
ognize both the recombinant protein/peptide and CSF in native 
conditions. At this stage, the type of ELISA plate should also be 
defined. The most common ELISA plate is the flat-bottomed 
96-well polystyrene microplate, which allows the adsorption of 
the antibodies to the well plate by hydrophobic interactions (low 
and medium binding). Nevertheless, high binding microplates 
are also available, in which the surface is modified by radiation 
to increase the binding strength between the antibodies and the 
plate (38).
Antibodies with proven specificity and ability to recognize 
the native protein in the human samples are the optimal ones for 
further immunoassay development. If no optimal antibodies are 
found, new antibodies detecting different epitopes should be pro-
duced. Usually, when good antibodies are produced, this phase 
will last approximately 3  months of one full-time equivalent, 
though it will also depend on the number of antibodies as well as 
the availability of all the reagents, samples, and expertise needed.
eLiSA Development
Antibody Pair Selection
A prerequisite for a good sandwich ELISA is that the two different 
antibodies (capture and detection antibodies) optimally match. 
Thus, the best antibody pairs able to detect the target CSF bio-
marker are identified by screening every possible combination. 
In order to avoid false positive measurements due to, e.g., direct 
reactivity between the antibodies, the optimal concentration 
of capture and detection antibodies for each combination has 
to be established. This can be done performing a checkerboard 
titration using the recombinant protein fragments/peptides (or 
full protein if available) at one fixed concentration (i.e., 0.5 μg/
mL) as a standard sample/calibrator (Figure  4C). As a start-
ing point, a concentration up to 2 and 10  μg/mL for capture 
and detection antibodies, respectively, can be tested. During 
the subsequent steps, it is recommended to always include the 
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standard calibrators and the pooled positive control CSF samples 
previously prepared (27).
Once the optimal antibody concentrations are established for 
each combination, both the standard sample and the CSF pools 
should be measured in serial dilutions to define which antibody 
pairs are able to detect the target CSF protein and the correspond-
ing standard in a dose–response manner. Dose–response reactiv-
ity gives a good indication that the antibody pairs are detecting 
the corresponding protein. Sample dilution experiments will 
unravel the standard curve range as well as the optimal dilution 
factor of the CSF. If dose–response reactivity is not acquired, this 
may indicate that the reactivity observed is non-specific. The 
source of the non-specific signal should be identified, which may 
arise among other possibilities from the detection system used 
(i.e., secondary antibodies) or an inadequate blocking buffer (see 
below). If the source of the non-specific signal is not identified 
and mitigated, the corresponding antibody pairs should not be 
used for further assay development.
Once results are successful, i.e., at least one or two positive 
antibody pairs are present, production of monoclonal antibodies 
recognizing the same epitopes can be considered. It is expected 
that the produced monoclonal antibodies will behave similar to 
the corresponding polyclonal due to the limited epitopes that 
were used for immunization of the latter. Depending on the 
number of antibodies to be tested and whether non-specific 
signal is detected, this phase may last from 3 to 10  months 
approximately.
Assay Set-Up and Fine-Tuning
The different conditions and reagents used (i.e., incubation 
times, blocking buffers, assay diluent, secondary antibodies) can 
also play a critical role in the development of an ELISA (38). 
Blocking buffers are used to cover the unoccupied hydrophobic 
spaces of the ELISA plate wells once capture antibodies have been 
coated, reducing subsequent non-specific binding of the sample/
reagents to the well. Different types of proteins are commonly 
used as a blocking agents, such as bovine serum albumin, non-
fat dry milk, casein, normal serum, or fish gelatin, which can 
be diluted at different concentrations (ranging from 1 to 5%) in 
either phosphate- or tris-buffer saline (PBS or TBS). The differ-
ent types of buffers and different protein concentrations should 
be tested since very low amount of blocking agent can lead to 
high background while excessive concentration may mask the 
binding epitope of the antibody. PBS can reduce signal of anti-
phospho-epitope-specific antibodies, and in that case, TBS will 
be the first choice and should likewise be used for sample dilu-
ent. Non-ionic detergents can be added to the sample dilution 
buffer, such as Tween20 that disrupts low affinity protein–protein 
interactions and increases contact of the H2O-component of the 
buffer to the surface. However, when background is high, it is 
recommended to add the protein used for blocking to the sample 
diluent, though at a lower concentration. This detergent buffer is 
also used during the washing steps between the different incuba-
tions of an ELISA procedure, but usually without added proteins. 
Selecting the optimal diluent helps to keep the background low, 
this will lead to an increase of sensitivity of the assay and can 
reduce matrix effects.
In addition to the buffer requirements, one should select the 
detection system used to create a quantitative signal. Enzymes 
(i.e., Horseradish Peroxidase, alkaline phosphatase) are com-
monly used, which are attached to either the detection antibody, 
to a secondary antibody or streptavidin when biotinylated 
detection antibodies are used. The enzyme reaction will produce 
a specific color once the corresponding chromogenic substrate 
or fluorochrome has been added (i.e., 3,5,3′,5′-tetramethylbenzi-
dine, p-nitrophenyl phosphate). The amount of signal generated 
within the linear range of the assay is proportional to the activity 
of enzyme present and thus, to the concentration of the target 
protein.
Once the different buffers and reagents have been established, 
it is recommended to re-test the optimal concentration of the 
coating and detection antibodies, since the improvements 
achieved with the different conditions may allow one to reduce 
the antibody concentration. Taking into account that only 
optimal antibody pairs are tested in this phase, it may take a 
maximum of 3 months to establish the best conditions leading 
to the highest signal/noise ratio for each of the antibody pairs. At 
this stage, a small number of individual patient samples should 
be tested. If available, it is recommended to use the same samples 
that were used during the discovery phase in order to replicate the 
proteomics findings (qualification).
eLiSA validation
initial eLiSA validation
Once an optimal assay has been developed or when it is commer-
cially available, it is essential to test its analytical performance 
in the appropriate matrix (i.e., CSF) before assessing the clini-
cal utility of the corresponding ELISA (28, 37, 39, 40). Several 
parameters need to be established such as precision, limits of 
detection, recovery, or parallelism among others. Validation of 
the assay will unravel whether the developed ELISA is accurate 
and robust in measuring the real levels of the candidate bio-
marker or if, on the contrary, the obtained values are influenced 
by other independent factors (i.e., pipetting errors, matrix effects, 
pre-analytical confounding factors). For example, the developed 
ELISA should have an optimal recovery, which is the ability of 
the assay to measure the specific candidate within the (complex) 
matrix (i.e., CSF) (41). During spike-recovery analysis, CSF 
samples with known concentration of the candidate biomarker 
are spiked with high, medium, low, and none amount of the cali-
brator. A bad recovery indicates that the different components 
of the matrix (i.e., CSF) affect the ability of the assay to measure 
the real concentration of the target molecule, which will affect 
the trueness of the results. Bad recoveries may be optimized 
by either using a different assay buffer mimicking better the 
matrix of interest or by further diluting the matrix of interest. 
ELISA validation will help to identify the different factors that 
compromise the reliability of the assay, which should be solved 
in order to draw accurate conclusions regarding the diagnostic 
performance of the biomarker candidate.
Previous guidelines have been published highlighting the 
parameters that should be stablished for the general validation 
of assays with different purposes (27, 41–45). This special issue 
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in Frontiers Neurology contains a step-by-step and consensus 
standardized operating procedure (SOP) for a thorough ELISA 
validation for biomarkers for neurodegeneration (Andreasson 
et  al.), developed by the members of the Joint Programming 
Neurodegenerative Disease (JPND) BIOMARKAPD (JPND-
BIOMARKAPD), a consortium aiming to standardize the bio-
marker analysis for Alzheimer’s and Parkinson’s disease across 
Europe (46).
The fulfillment of the different parameters established by the 
JPND-BIOMARKAPD consortium as described by Andreasson 
and colleagues suggests that the assay is accurately measuring the 
candidate biomarker in CSF and thus a proof-of-concept analysis 
(verification) can be performed with a small cohort of individual 
samples (approximately 20 samples per clinical group). In case 
that some of the parameters are not fulfilled, it is recommended 
to re-analyze and test some of the incubation times, reagents, 
and concentrations established during assay development. Even 
if no changes in the concentration of the biomarker candidate 
are detected between the different clinical groups, it is worth to 
continue with a full-assay validation, since the assay might also 
be useful for other research purposes besides biomarker valida-
tion. However, full validation can only be performed on the final 
version of the assay. Noteworthy, when other matrices are used 
(i.e., post-mortem tissue, cell culture supernatants, cell lysates), 
an additional validation should always be performed to confirm 
the suitability of the assay for the corresponding matrix. The time 
frame for the completion of this phase typically lies between 2 
and 8 months.
Full eLiSA validation
Once the new ELISA is fully developed, the novel assay should 
undergo an extensive validation for the targeted matrix in which 
other important parameters, including the reproducibility or the 
robustness of the assay, are tested as also indicated by Andreasson 
and colleagues in the current issue. The stability of the candidate 
biomarker under certain conditions should be also analyzed. 
Although the effect of pre-analytical variables have been likely 
minimized if the general guidelines for sample handling have 
been followed (31), some of the pre-analytical confounding fac-
tors should be specifically measured for the biomarker candidate 
to detect possible effects induced by different pre-analytical issues. 
Pre-analytical confounding factors include not only patient vari-
ables such as diurnal variation and fasting, but also processing 
factors such as the effect of freeze/thaw cycles and length of stor-
age at different temperatures (28, 32, 47).
Since samples need to be prepared for pre-analytical vari-
ability testing (including storage over long time), this phase can 
take between 4 months and even a couple of years for long-term 
storage. Although the fulfillment of a complete ELISA validation 
ensures that the assay is suitable to measure the targeted molecule 
in the validated matrix, it is important to note that assay valida-
tion is a continuous process since reagents are continuously being 
renewed (i.e., quality control samples, standards, primary, and 
secondary antibodies). Thus, batch-to-batch variations should 
be always analyzed, tracked, and reported and, if needed, valida-
tion should be re-tested and an internal quality control program 
should be initiated. Nevertheless, since biomarker validation is a 
continuous process, current guidelines and workflows will have 
to be revised and updated regularly.
Clinical Assessment of the Biomarker
The different processes followed until this point allow to suc-
cessfully develop and to analytically validate an assay that can 
specifically and accurately measure the novel discovered CSF 
biomarker candidate. In this latest stage, the assay can be used 
for clinical validation of the biomarker for the intended purpose 
(i.e., diagnosis, prognosis, treatment efficiency). A considerably 
larger number of samples must be analyzed compared to the 
discovery phase and thus a power analysis should be performed 
in order to define the optimal group size. Specificity and sensi-
tivity of the corresponding biomarker should be calculated and 
the ability of the biomarker to discriminate between control and 
disease can be assessed using the receiver operating characteristic 
(ROC) curve and the area under the curve (AUC), alone and/
or in combination with currently used CSF biomarker tests (i.e., 
Aβ42, t-Tau, and p-Tau in AD) (48). According to international 
dementia biomarker criteria, a sensitivity and specificity of at 
least 85% is needed for a clinically useful biomarker (49). If a 
longitudinal study is performed, it might also be useful to assess 
the predictive value of the biomarkers that reflect the conversion 
from non-demented or mild cognitive impairment cases to the 
specific dementia with Cox proportional hazards models and 
Kaplan–Meier curves (50). When positive results are obtained, 
data should be independently replicated using larger cohorts, 
different populations and multi-center studies before its future 
possible implementation in routine analysis (51, 52).
Concluding Remarks and Perspectives for 
Future Assay implementation in Routine 
Analysis
There is a great need to develop specific, sensitive, and practical 
tools to differentially diagnose AD and related dementias in its 
earliest possible phase. The gold standard format for biomarker 
analysis is ELISA, which usually needs to be developed when 
a novel biomarker candidate is identified. In order to facilitate 
the development of a novel ELISA and ease the validation of the 
potential candidate CSF biomarkers, here we suggest a straight-
forward workflow for ELISA development, which we divided 
into four different steps (Figure  2). In each step, different key 
issues need to be tested (Table 1). When a commercial ELISA is 
available, the corresponding assay should be validated for its use 
in the corresponding matrix (i.e., CSF) (Figure 2, step 3). In the 
last steps, a clinical assessment of the biomarker candidate should 
be performed using the validated ELISA.
Once the optimal assay has been fully developed and validated, 
and the diagnostic utility of the corresponding biomarker has 
been solidly established, it will be necessary to initiate the phase 
that will ultimately lead to the implementation of the diagnostic 
assay in routine diagnosis, i.e., to establish an in vitro diagnostic 
(IVD) test. Such tests are preferably developed on an automated 
platform (53, 54), which will strongly reduce variation between 
centers allowing the establishment of cut-off values. In order to 
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implement in clinical practice, several governmental require-
ments need to be fulfilled, which can range from the reproduc-
ibility and stability of the analytical platform to proof of added 
diagnostic value of the discovered biomarker. The exact set of 
rules that need to be complied to implement an IVD test depends 
on the regulatory institution of each region, which is, for example, 
the 510(k) premarketing clearance oversight by the food and 
drug administration in United States (55) or the IVD Directive 
98/97/EC established by the European Commission (56).
Developing a successful ELISA for the validation of novel 
protein biomarker candidates starts by taking the right decisions 
during early stages of the development, for which we believe 
the workflow described in this paper will be a very useful aid.
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